International Association for Hospice and Palliative Care Inc.

Printer-friendly version
144th session of the Executive Board<br>24 January - 1 February 2019
Agenda Item: 
5.7.1 Access to medicines and vaccines

IAHPC thanks the Secretariat for the Report and references to controlled medicines. IAHPC participated in the Roadmap process. We will assure the Secretariat that IAHPC will continue to work with them on refining indicators in the context of balanced drug policies in order to follow recommendations of UNGASS2016, working with WHO EMP division, Service Delivery and Safety, UNODC and INCB.
The following is a problematic sentence in the Report:
i. [WHO will provide] “Support for improved forecasting and quantification of controlled medicines to avoid over-stock and support for strengthened capacity of prescribers and dispensers to ensure the quality of service and minimize the risk of diversion.”
IAHPC and our members identifies stockouts and understock as the usual problems.
Governments can remedy the problem of stockouts and understocking, which leave people in terrible suffering by ensuring a strong supply chain and training pharmacists, nurses and doctors, including medical officers to prescribe controlled medicines.
We have a question about the following deliverable:
ii. “Support for the development of national policies and regulations to ensure access, appropriate prescribing, dispensing and use of controlled medicines, including guidance on optimizing relevant legislation and support for strengthening the capacity of prescribers and dispensers to ensure access and quality of service and minimize the risk of diversion.”
What form will this “support” take? In the light of the Astana Declaration, will countries be supported improve regulations to help train and empower family doctors?